TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15468020

Group type: EXPERIMENTAL
Intervention: Task-related training (TRT) for low-level subjects
Number of subjects: 12

Group type: COMPARATOR
Intervention: Progressive resistive exercise (PRE) for low-level subjects
Number of subjects: 12

Group type: COMPARATOR
Intervention: Progressive resistive exercise (PRE) for high-level subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Task-related training (TRT) for high-level subjects
Number of subjects: 12
Study: 11441198

Group type: EXPERIMENTAL
Intervention: Enalapril at 10 mg/d (n=48)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Enalapril use
Number of subjects: 98
Study: 8883531

Group type: EXPERIMENTAL
Intervention: iodixanol at 270 mg I/ml (IOD-270)
Number of subjects: 99

Group type: COMPARATOR
Intervention: iohexol at 300 mg I/ml (IOH-300)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both iodixanol and iohexol
Number of subjects: 99
Study: 1562096

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg i.v. 10 min prior to intubation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg i.m. 30 min prior to intubation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no atropine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine (both i.m. and i.v.)
Number of subjects: 80
Study: 4056240

Group type: EXPERIMENTAL
Intervention: Intravenous injection of hydrocortisone (300 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Solvent (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous injections of 20 mg of methylprednisolone, 4 mg of dexamethasone, or 4 mg of betamethasone
Number of subjects: 31
Study: 31703707

Group type: EXPERIMENTAL
Intervention: SMG-based health-promoting lifestyles interventions for 7 months
Number of subjects: 350
Study: 30390875

Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27291327

Group type: EXPERIMENTAL
Intervention: CRT-D with Telemonitoring (TM)
Number of subjects: 191

Group type: COMPARATOR
Intervention: CRT-D with traditional ambulatory monitoring (control group)
Number of subjects: 191
Study: 24531833

Group type: EXPERIMENTAL
Intervention: P300 concealed information test with 33, 66, and 100 trial averages
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-stimulus protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complex trial protocol
Number of subjects: 0
Study: 22734581

Group type: EXPERIMENTAL
Intervention: Paracetamol i.v. 1 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paracetamol i.v. 2 g
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxycodone i.v. (0.1 mg/kg)
Number of subjects: 24
Study: 19841862

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 30
Study: 17564290

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active smoking status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LDL cholesterol levels
Number of subjects: 100
Study: 16096182

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 192

Group type: COMPARATOR
Intervention: Clobetasol propionate emollient cream
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 192
Study: 12322819

Group type: COMPARATOR
Intervention: Fluid status assessment using tracer dilution techniques (ECV, TBW, PV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fluid status assessment (TBW:BSA, ECV:BSA, PV:BSA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Arterial distensibility assessment of the common carotid artery
Number of subjects: 41

Group type: COMPARATOR
Intervention: ECV assessment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Arterial distensibility assessment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ambulatory BP measurements
Number of subjects: 41

Group type: COMPARATOR
Intervention: Office BP measurements
Number of subjects: 41
Study: 10419988

Group type: EXPERIMENTAL
Intervention: AHA Step I diet with targeted reduction in energy intake of approximately 1000 kJ/d for 6 months
Number of subjects: 6
Study: 7677684

Group type: EXPERIMENTAL
Intervention: Stopped smoking
Number of subjects: 197

Group type: COMPARATOR
Intervention: Continued to smoke
Number of subjects: 197
Study: 2013244

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.5 g plus amikacin 500 mg i.v. 2 h before surgery and the same doses per 8 or 12 h for 2 days postoperatively (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ornidazole 1 g by intravenous infusion plus ceftriaxone 2 g i.v. 2 h before surgery and the same doses per 24 h for 2 days postoperatively (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ornidazole plus ceftriaxone
Number of subjects: 50
Study: 7106840

Group type: EXPERIMENTAL
Intervention: Spleen exposure to ultrasound (2.0 mW/m2, 3.5 MHz, 5 minutes)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 31233220

Group type: EXPERIMENTAL
Intervention: Colonic J pouch
Number of subjects: 379

Group type: COMPARATOR
Intervention: Straight colorectal anastomosis
Number of subjects: 379
Study: 28872774

Group type: COMPARATOR
Intervention: No Drain Placement (ND)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Pelvic Drain Placement (PD)
Number of subjects: 189
Study: 27557121

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) + Temozolomide (TMZ) for seven weeks followed by radiotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) + Temozolomide (TMZ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) for eight weeks followed by concomitant radiotherapy and TMZ
Number of subjects: 40
Study: 24723147

Group type: EXPERIMENTAL
Intervention: Rivastigmine (mean dose 5.1 ± 2.3 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 22287221

Group type: EXPERIMENTAL
Intervention: Two 8 Gy doses of external beam radiation
Number of subjects: 7

Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 7
Study: 20481041

Group type: EXPERIMENTAL
Intervention: Imunofan combined with basic therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 69
Study: 17277350

Group type: EXPERIMENTAL
Intervention: Primary Angioplasty
Number of subjects: 7518

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 7518
Study: 15012924

Group type: EXPERIMENTAL
Intervention: 3-month aerobic program above standard treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment without special advice for exercise
Number of subjects: 34
Study: 11603100

Group type: EXPERIMENTAL
Intervention: Keto acids/amino acids (KA) supplementation at a dosage of 100 mg/kg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: No supplementation (Control Group II)
Number of subjects: 38
Study: 9587722

Group type: EXPERIMENTAL
Intervention: Bupivacaine-Midazolam (0.125% bupivacaine 0.75 mL kg‐1 with 0.5% midazolam 50 micrograms kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine-Morphine (0.125% bupivacaine 0.75 mL kg‐1 with 1% morphine chlorhydrate 0.05 mg kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine alone (0.125% bupivacaine 0.75 mL kg‐1)
Number of subjects: 60
Study: 7985754

Group type: EXPERIMENTAL
Intervention: Acridine orange staining method
Number of subjects: 49

Group type: COMPARATOR
Intervention: Thick blood film
Number of subjects: 49
Study: 2907749

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31004523

Group type: EXPERIMENTAL
Intervention: Oral function intervention only
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nutritional intervention only
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combined oral function plus nutritional intervention
Number of subjects: 83
Study: 28993388

Group type: EXPERIMENTAL
Intervention: Basic medication reminder app group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Advanced medication reminder app group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study: 25778987

Group type: EXPERIMENTAL
Intervention: 200 mg of American ginseng (Panax quinquefolius)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22270179

Group type: EXPERIMENTAL
Intervention: Walking for 1 hour
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bed rest for 1 hour
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1-hour labor check evaluation
Number of subjects: 63
Study: 20078486

Group type: EXPERIMENTAL
Intervention: Implicit training to avoid alcohol (avoid-alcohol condition)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Implicit training to approach alcohol (approach-alcohol condition)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Automatic action tendencies assessed with the AAT and IAT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subjective craving assessment
Number of subjects: 42
Study: 16169582

Group type: EXPERIMENTAL
Intervention: Comprehensive follow-up guidance system
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Selective follow-up guidance system
Number of subjects: 2250
Study: 12076867

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 99

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 99
Study: 10457386

Group type: EXPERIMENTAL
Intervention: Selegiline combined with levodopa and benserazide
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo combined with levodopa and benserazide
Number of subjects: 163
Study: 8678259

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 40
Study: 2130002

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 60-80 mg/kg/day intramuscularly for 5-7 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chloramphenicol 50-80 mg/kg/day orally in 4 divided doses for 12-14 days
Number of subjects: 55
Study: 371646

Group type: EXPERIMENTAL
Intervention: Intravenous mexiletine (150 mg bolus injection)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 16
Study: 31535807

Group type: EXPERIMENTAL
Intervention: SpermActin Forte, 1 sachet of 10 g once a day for 180 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 180 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SpermActin Forte
Number of subjects: 80
Study: 29217455

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses with yellow filter (YF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monovision contact lenses without far prescription
Number of subjects: 20
Study: 26433727

Group type: EXPERIMENTAL
Intervention: Rapid clozapine titration (started at 25-50 mg, increased by 50-100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow clozapine titration (started at 12.5-50 mg, increased by 25-50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid clozapine titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow clozapine titration
Number of subjects: 0
Study: 24673714

Group type: EXPERIMENTAL
Intervention: Standard dose (SD) of enteric-coated mycophenolate sodium (1440 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low dose (LD) of enteric-coated mycophenolate sodium (1080 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard dose (SD) of enteric-coated mycophenolate sodium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low dose (LD) of enteric-coated mycophenolate sodium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both SD and LD groups
Number of subjects: 60
Study: 22530305

Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:5 ratio)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:10 ratio)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:20 ratio)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Approved oral Ibandronate tablet formulations (150 mg IBN)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Increasing post-dose fasting duration from 15 to 30 min
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IBN/SNAC treatments
Number of subjects: 97
Study: 20598044

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 112

Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 112
Study: 18613441

Group type: EXPERIMENTAL
Intervention: Postoperative prophylactic irrigation around the pancreaticojejunostomy for 72 hours starting from postoperative day 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-irrigation (control group)
Number of subjects: 50
Study: 15752384

Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g day(-1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12584786

Group type: EXPERIMENTAL
Intervention: Rhubarb powder orally or by nasal feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rhubarb treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 40
Study: 10550952

Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal repair
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 50
Study: 7583542

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (bicycle ergometer at about 60% of maximal oxygen consumption for 30 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deconditioning (12 weeks after training)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Short-term strenuous exercise
Number of subjects: 100
Study: 2258297

Group type: EXPERIMENTAL
Intervention: Interferon Alfa‐2b (Intron A) administered at a low-dose regimen (1 million I.U. s.c. daily for 6 days with a 2-week interval between courses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6786074

Group type: EXPERIMENTAL
Intervention: Cysteine supplementation (77 mg/kg/24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intravenous formulations
Number of subjects: 0
Study: 29679529

Group type: EXPERIMENTAL
Intervention: Parenteral ω‐3 LC‐PUFAs (EPA and DHA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clinoleic (Baxter Medical AB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SMOFlipid (Fresenius Kabi)
Number of subjects: 90

Group type: COMPARATOR
Intervention: None of the parenteral lipid emulsions
Number of subjects: 90
Study: 28993871

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 μg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0
Study: 25039675

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 416

Group type: COMPARATOR
Intervention: Exenatide vs Insulin
Number of subjects: 416

Group type: COMPARATOR
Intervention: Exenatide vs Pioglitazone
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 416
Study: 23825411

Group type: EXPERIMENTAL
Intervention: Activation of the contralesional hippocampus and increased engagement of a distributed short‐term memory network in neocortex during an associative short‐term memory task.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intact associative short‐term memory despite hippocampal dysfunction.
Number of subjects: 2
Study: 22010409

Group type: COMPARATOR
Intervention: Occlusal stabilization splint (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Soft occlusal splint (experimental group)
Number of subjects: 16
Study: 19009634

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 2.0-2.5 mg/kg a day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Budesonide (BUD) 6-9 mg a day
Number of subjects: 77
Study: 18812202

Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7) at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost)
Number of subjects: 0

Group type: COMPARATOR
Intervention: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7)
Number of subjects: 0
Study: 16033861

Group type: EXPERIMENTAL
Intervention: Trisodium citrate 30%
Number of subjects: 291

Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 291
Study: 12161521

Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10094079

Group type: EXPERIMENTAL
Intervention: Week-long training program
Number of subjects: 179000

Group type: EXPERIMENTAL
Intervention: 2-week-long training program
Number of subjects: 179000
Study: 7595793

Group type: EXPERIMENTAL
Intervention: Simultaneous bone grafting
Number of subjects: 20

Group type: COMPARATOR
Intervention: No bone grafting
Number of subjects: 20
Study: 2241335

Group type: EXPERIMENTAL
Intervention: St. Jude Medical prosthesis
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medtronic-Hall prosthesis
Number of subjects: 182
Study: 99089

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nebulised water
Number of subjects: 14
Study: 31804404

Group type: EXPERIMENTAL
Intervention: Controlled ventilation with muscle relaxants (MR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Spontaneous respiration (SP)
Number of subjects: 64
Study: 30843263

Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28146560

Group type: EXPERIMENTAL
Intervention: Loss-framed texts (LF)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Gain-framed texts (GF)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Static tailored texts (ST)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Adaptive tailored texts (TA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Weekly drink self-tracking mobile assessment texts (MA)
Number of subjects: 152
Study: 26201694

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg/h of glucose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 16
Study: 23958074

Group type: EXPERIMENTAL
Intervention: 20 μg of oral T3 every 12 hours starting 20 minutes before anesthetic induction, for a total of 4 doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21362360

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 47
Study: 19190958

Group type: EXPERIMENTAL
Intervention: Citalopram (20mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fluoxetine (20mg)
Number of subjects: 29
Study: 17141739

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU Syntocinon)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15508663

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging performed immediately before and after ET tube placement
Number of subjects: 59
Study: 11422695

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Composite resin (CR)
Number of subjects: 117
Study: 9773912

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (EXOSURF Neonatal)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Air-treated control
Number of subjects: 83
Study: 8153781

Group type: EXPERIMENTAL
Intervention: 10 mg of ketorolac orally
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 10 mg of morphine intramuscularly
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 5 mg of morphine intramuscularly
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 2894169

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Encainide and Flecainide in patients who failed Imipramine or Moricizine
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Encainide, Flecainide, and Moricizine
Number of subjects: 502
Study: 31398065

Group type: EXPERIMENTAL
Intervention: UCLA group (n = 25)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: UCLP group (n = 23)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BCLP group (n = 22)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 84
Study: 31192549

Group type: EXPERIMENTAL
Intervention: Rice group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Steamed buns group
Number of subjects: 22
Study: 27548886

Group type: EXPERIMENTAL
Intervention: 50 mg CoQ10 supplementation for 12 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 150 mg CoQ10 supplementation for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25516073

Group type: EXPERIMENTAL
Intervention: Patient navigation plus printed educational materials (PEM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient navigation plus PEM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Printed educational materials (PEM)
Number of subjects: 100